Xianhua Gu, Honghong Shen, Zheng Xiang, Xinwei Li, Yue Zhang, Rong Zhang, Fang Su, Zishu Wang
{"title":"Exploring the Correlation Between <i>GPR176</i>, a Potential Target Gene of Gastric Cancer, and Immune Cell Infiltration.","authors":"Xianhua Gu, Honghong Shen, Zheng Xiang, Xinwei Li, Yue Zhang, Rong Zhang, Fang Su, Zishu Wang","doi":"10.2147/PGPM.S411199","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong><i>GPR176</i>, an orphan G protein-coupled receptor (GPCR), is essential for the progression of gastrointestinal cancers. However, it is still unclear how <i>GPR176</i> affects tumor immunity and patient prognosis in gastric cancer (GC).</p><p><strong>Methods: </strong>The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) were searched in this investigation to assess the expression patterns of <i>GPR176</i> in GC tissues and normal gastric mucosa. The findings were further verified using immunohistochemical tests and quantitative Real-Time Polymerase Chain Reaction (qRT-PCR). The Kaplan-Meier method, univariate logistic regression, and Cox regression were then used to investigate the relationship between <i>GPR176</i> and clinical traits. Additionally, the potential correlation between <i>GPR176</i>, immune checkpoint genes, and immune cell infiltration levels was investigated.</p><p><strong>Results: </strong>As per the research findings, GC tissues had higher levels of <i>GPR176</i> than normal tissues. Additionally, individuals with high expression of <i>GPR176</i> had a worse 10-year overall survival (OS), in contrast with those having a low expression of <i>GPR176</i> (<i>p</i> < 0.001). The OS of GC can be predicted using a validated nomogram model. The expression of <i>GPR176</i> demonstrated a negative correlation with CD8+ T cells. When compared to the low-expression group of <i>GPR176</i>, Tumor Immune Dysfunction and Exclusion (TIDE) analysis demonstrated that the high-expression group had a considerably higher risk of immune evasion. A remarkable difference (variation) was observed in the levels of <i>GPR176</i> expression across both groups, ie, low and high-risk groups, as determined by the immune phenomenon scores (IPS) immunotherapy assessment.</p><p><strong>Conclusion: </strong>By examining <i>GPR176</i> from various biological perspectives, it was determined that <i>GPR176</i> can act as a predictive biomarker for poor patient prognosis in GC. Additionally, it was observed that <i>GPR176</i> is capable of suppressing the proliferation of CD8+ T cells and facilitating immune evasion.</p>","PeriodicalId":56015,"journal":{"name":"Pharmacogenomics & Personalized Medicine","volume":"16 ","pages":"519-535"},"PeriodicalIF":1.8000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/43/db/pgpm-16-519.PMC10241216.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmacogenomics & Personalized Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2147/PGPM.S411199","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0
Abstract
Introduction: GPR176, an orphan G protein-coupled receptor (GPCR), is essential for the progression of gastrointestinal cancers. However, it is still unclear how GPR176 affects tumor immunity and patient prognosis in gastric cancer (GC).
Methods: The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) were searched in this investigation to assess the expression patterns of GPR176 in GC tissues and normal gastric mucosa. The findings were further verified using immunohistochemical tests and quantitative Real-Time Polymerase Chain Reaction (qRT-PCR). The Kaplan-Meier method, univariate logistic regression, and Cox regression were then used to investigate the relationship between GPR176 and clinical traits. Additionally, the potential correlation between GPR176, immune checkpoint genes, and immune cell infiltration levels was investigated.
Results: As per the research findings, GC tissues had higher levels of GPR176 than normal tissues. Additionally, individuals with high expression of GPR176 had a worse 10-year overall survival (OS), in contrast with those having a low expression of GPR176 (p < 0.001). The OS of GC can be predicted using a validated nomogram model. The expression of GPR176 demonstrated a negative correlation with CD8+ T cells. When compared to the low-expression group of GPR176, Tumor Immune Dysfunction and Exclusion (TIDE) analysis demonstrated that the high-expression group had a considerably higher risk of immune evasion. A remarkable difference (variation) was observed in the levels of GPR176 expression across both groups, ie, low and high-risk groups, as determined by the immune phenomenon scores (IPS) immunotherapy assessment.
Conclusion: By examining GPR176 from various biological perspectives, it was determined that GPR176 can act as a predictive biomarker for poor patient prognosis in GC. Additionally, it was observed that GPR176 is capable of suppressing the proliferation of CD8+ T cells and facilitating immune evasion.
期刊介绍:
Pharmacogenomics and Personalized Medicine is an international, peer-reviewed, open-access journal characterizing the influence of genotype on pharmacology leading to the development of personalized treatment programs and individualized drug selection for improved safety, efficacy and sustainability.
In particular, emphasis will be given to:
Genomic and proteomic profiling
Genetics and drug metabolism
Targeted drug identification and discovery
Optimizing drug selection & dosage based on patient''s genetic profile
Drug related morbidity & mortality intervention
Advanced disease screening and targeted therapeutic intervention
Genetic based vaccine development
Patient satisfaction and preference
Health economic evaluations
Practical and organizational issues in the development and implementation of personalized medicine programs.